跳轉至內容
Merck
全部照片(1)

重要文件

1435003

USP

甲基强的松龙

United States Pharmacopeia (USP) Reference Standard

同義詞:

6α-甲基泼尼松龙, 11β,17α,21-三羟基-6α-甲基-1,4-孕甾二烯-3,20-二酮, 6α-甲基-11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮, 甲基强的松龙, 甲基泼尼松龙

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C22H30O5
CAS號碼:
分子量::
374.47
Beilstein:
2340300
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

methylprednisolone

製造商/商標名

USP

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)CO

InChI

1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

InChI 密鑰

VHRSUDSXCMQTMA-PJHHCJLFSA-N

基因資訊

human ... NR3C1(2908)

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Methylprednisolone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Methylprednisolone Sodium Succinate for Injection
  • Methylprednisolone Tablets

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

相關產品

產品號碼
描述
訂價

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Repr. 1B - STOT RE 2

標靶器官

Adrenal gland,Immune system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 2


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Tyree H Kiser et al.
American journal of respiratory and critical care medicine, 189(9), 1052-1064 (2014-03-13)
Studies evaluating corticosteroid (CS) dosing for patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) have largely excluded patients admitted directly to the intensive care unit (ICU), and none have evaluated the effect of CS dosing regimens
Fungal infections associated with contaminated methylprednisolone injections.
Carol A Kauffman et al.
The New England journal of medicine, 368(26), 2495-2500 (2012-10-23)
Amy L Samuels et al.
British journal of haematology, 165(1), 57-66 (2014-01-25)
Drug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children. Up to 25% of patients with T-cell ALL (T-ALL) develop resistance to chemotherapeutic agents, particularly to glucocorticoids (GCs), a class of drug to
M Toledano et al.
Neurology, 82(18), 1578-1586 (2014-04-08)
To evaluate a trial of immunotherapy as an aid to diagnosis in suspected autoimmune epilepsy. We reviewed the charts of 110 patients seen at our autoimmune neurology clinic with seizures as a chief complaint. Twenty-nine patients met the following inclusion
Young-tae Kim et al.
Biomaterials, 30(13), 2582-2590 (2009-02-03)
Systemic administration of a high-dose of Methylprednisolone (MP) can reduce neurological deficits after acute spinal cord injury (SCI). However, the use of high-dose MP in treating acute SCI is controversial due to significant dose related side effects and relatively modest

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務